Leidse hoogleraren vanaf 1575

Meindert Danhof

Geboren
1951-12-30 te Groningen, Nederland
Geslacht
Man

Promotie (1980)

Type examen
Promotie
Datum
1980-10-23
Plaats
Leiden
Proefschrift
Antipyrine metabolite profile as a tool in the assessment of the activity of different drug oxidising enzymes in man

Gewoon hoogleraar (1996)

Benoeming
Gewoon hoogleraar
Faculteit
Geneeskunde, Wiskunde en Natuurwetenschappen
Vakgebied
Farmacologie
Leeropdracht
Farmacologie
Datum benoeming
1996
Datum oratie
1997-04-11
Titel oratie
Farmacologie in spiegelbeeld

Publicaties

Wetenschappelijk
  • Witte W.E.A. de, Danhof M., Graaf P.H. van der & Lange E.C.M. de (2016), In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant., Trends in pharmacological sciences 37(10): 831-842.
  • Calvier E.A.M., Krekels E.H.J., Välitalo P.A.J., Rostami-Hodjegan A., Tibboel D., Danhof M. & Knibbe C.A.J. (2016), Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?, Clinical Pharmacokinetics 2016.
  • Bakshi S.D., Lange E.C.M. de, Graaf P.H. van der, Danhof M. & Peletier L.A. (2016), Understanding the Behavior of Systems Pharmacology Models Using Mathematical Analysis of Differential Equations: Prolactin Modeling as a Case Study, CPT: Pharmacometrics & Systems Pharmacology 5(7): 339-351.
  • Hasselt J.G. van, Rizk M.L., Lala M., Chavez-Eng C, Visser S.A., Kerbusch T., Danhof M., Rao G. & Graaf P.H. van der (2016), Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid, British Journal of Clinical Pharmacology 81: 1113–1123.
  • Dubois V.F.S., Witte W.E.A. de, Visser S.A., Danhof M. & Della Pasqua O. (2016), Assessment of Interspecies Differences in Drug-Induced QTc Interval Prolongation in Cynomolgus Monkeys, Dogs and Humans., PHARMACEUTICAL RESEARCH 33(1): 40-51.
  • Brill M.J.E., Välitalo P.A.J., Darwich A.S., Ramshorst B. van, Dongen H.P. van, Rostami-Hodjegan A., Danhof M. & Knibbe C.A. (2016), Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1-OH-midazolam in morbidly obese and weight loss surgery patients, CPT: Pharmacometrics & Systems Pharmacology 5(1): 20-30.
  • Witte W.E., Wong Y.C., Nederpelt I., Heitman L.H., Danhof M., Graaf P.H. van der, Gilissen R.A. & de Lange E.C. (2016), Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients., Expert opinion on drug discovery 11(1): 45-63.
  • Bellanti F., Vecchio G.C. Del, Putti M.C., Cosmi C., Fotzi I., Bakshi S.D., Danhof M. & Della Pasqua O.E. (2015), Model-Based Optimisation of Deferoxamine Chelation Therapy, PHARMACEUTICAL RESEARCH 33(2): 498-509.
  • Dubois Vincent F. S., Yu Huixin, Danhof Meindert & Della Pasqua Oscar (2015), Model-based evaluation of drug-induced QTc prolongation for compounds in early development, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 79(1): 148-161.
  • Bellanti F., Wijk R.C. van, Danhof M. & Della Pasqua O.E. (2015), Integration of PKPD relationships into benefit-risk analysis, British Journal of Clinical Pharmacology 80(5): 979-991.
  • Krekels E.H.J., Ham, S. van, Allegaert K., Hoon J. de, Tibboel D., Danhof M. & Knibbe C.A.J. (2015), Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants., European Journal of Clinical Pharmacology 71(9): 1075-82.
  • Bellanti Francesco, Danhof Meindert & Della Pasqua Oscar (2014), Population pharmacokinetics of deferiprone in healthy subjects, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 78(6): 1397-1406.
  • Romero Klaus, Sinha Vikram, Allerheiligen Sandra, Danhof Meindert, Pinheiro Jose, Kruhlak Naomi, Wang Yaning, Wang Sue-Jane, Sauer John-Michael, Marier J. F., Corrigan Brian, Rogers James, Heerspink H. J. Lambers, Gumbo Tawanda, Vis Peter, Watkins Paul, Morrison Tina, Gillespie William, Gordon Mark Forrest, Stephenson Diane, Hanna Debra, Pfister Marc, Lalonde Richard & Colatsky Thomas (2014), Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop, JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 41(6): 545-552.
  • Mochel Jonathan P., Fink Martin, Bon Charlotte, Peyrou Mathieu, Bieth Bruno, Desevaux Cyril, Deurinck Mark, Giraudel Jerome M. & Danhof Meindert (2014), Influence of feeding schedules on the chronobiology of renin activity, urinary electrolytes and blood pressure in dogs, CHRONOBIOLOGY INTERNATIONAL 31(5): 715-730.
  • Dubois Vincent F. S., van der Graaf Piet, Leishman Derek, Gallacher David, McMahon Nick, Visser Sandra, Danhof Meindert & Della Pasqua Oscar (2014), Translating the gap in the evaluation of drug-induced QTc-interval prolongation from in vivo to the clinic, JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS 70(3): 324-324.
  • Snelder N., Ploeger B. A., Luttringer O., Rigel D. F., Fu F., Beil M., Stanski D. R. & Danhof M. (2014), Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling, BRITISH JOURNAL OF PHARMACOLOGY 171(22): 5076-5092.
  • Cock R.F.W. de, Allegaert K., Brussee J.M., Sherwin C.M., Mulla H., Hoog M. de, Anker J.N. van den, Danhof M. & Knibbe C.A.J. (2014), Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration., PHARMACEUTICAL RESEARCH 31(10): 2643-2654.
  • De Cock Roosmarijn F. W., Allegaert Karel, Brussee Janneke M., Sherwin Catherine M. T., Mulla Hussain, de Hoog Matthijs, van den Anker Johannes N., Danhof Meindert & Knibbe Catherijne A. J. (2014), Simultaneous Pharmacokinetic Modeling of Gentamicin, Tobramycin and Vancomycin Clearance from Neonates to Adults: Towards a Semi-physiological Function for Maturation in Glomerular Filtration, PHARMACEUTICAL RESEARCH 31(10): 2643-2654.
  • Johnson Martin, Kozielska Magdalena, Reddy Venkatesh Pilla, Vermeulen An, Barton Hugh A., Grimwood Sarah, de Greef Rik, Groothuis Geny M. M., Danhof Meindert & Proost Johannes H. (2014), Dopamine D2 Receptor Occupancy as a Predictor of Catalepsy in Rats: A Pharmacokinetic-Pharmacodynamic Modeling Approach, PHARMACEUTICAL RESEARCH 31(10): 2605-2617.
  • Knibbe C.A., Brill M.J., van Rongen A., Diepstraten J., van der Graaf P.H. & Danhof M. (2015), Drug disposition in obesity: toward evidence-based dosing, Annu Rev Pharmacol Toxicol. 55: 149-67.
  • Strougo Ashley, Yassen Ashraf, Monnereau Claire, Danhof Meindert & Freijer Jan (2014), Predicting the "First dose in children" of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young ages, JOURNAL OF CLINICAL PHARMACOLOGY 54(9): 1006-1015.
  • Snelder Nelleke, Ploeger Bart A., Luttringer Olivier, Stanski Donald. R. & Danhof Meindert (2014), Translational Pharmacokinetic Modeling of Fingolimod (FTY720) as a Paradigm Compound Subject to Sphingosine Kinase-Mediated Phosphorylation, DRUG METABOLISM AND DISPOSITION 42(9): 1367-1378.
  • Musuamba F.T., Teutonico D., Maas H.J., Facius A., Yang S., Danhof M. & Della Pasqua O. (2015), Prediction of Disease Progression, Treatment Response and Dropout in Chronic Obstructive Pulmonary Disease (COPD), Pharmaceutical Research 32(2): 617-27.
  • Sahota Tarjinder, Sanderson Ian, Danhof Meindert & Della Pasqua Oscar (2014), Model-based analysis of thromboxane B-2 and prostaglandin E-2 as biomarkers in the safety evaluation of naproxen, TOXICOLOGY AND APPLIED PHARMACOLOGY 278(3): 209-219.
  • Piana Chiara, Danhof Meindert & Della Pasqua Oscar (2014), Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 78(1): 145-157.
  • Krekels Elke H. J., Tibboel Dick, de Wildt Saskia N., Ceelie Ilse, Dahan Albert, van Dijk Monique, Danhof Meindert & Knibbe Catherijne A. J. (2014), Evidence-Based Morphine Dosing for Postoperative Neonates and Infants, CLINICAL PHARMACOKINETICS 53(6): 553-563.
  • Wang Chenguang, Allegaert Karel, Tibboel Dick, Danhof Meindert, van der Marel Caroline D., Mathot Ron A. A. & Knibbe Catherijne A. J. (2014), Population Pharmacokinetics of Paracetamol Across the Human Age-Range From (Pre) term Neonates, Infants, Children to Adults, JOURNAL OF CLINICAL PHARMACOLOGY 54(6): 619-629.
  • De Cock Roosmarijn F. W., Allegaert Karel, Vanhaesebrouck Sophie, de Hoon Jan, Verbesselt Rene, Danhof Meindert & Knibbe Catherijne A. J. (2014), Low but Inducible Contribution of Renal Elimination to Clearance of Propylene Glycol in Preterm and Term Neonates, THERAPEUTIC DRUG MONITORING 36(3): 278-287.
  • Piana Chiara, Zhao Wei, Adkison Kimberly, Burger David, Jacqz-Aigrain Evelyne, Danhof Meindert & Della Pasqua Oscar (2014), A model- based approach for the evaluation of once daily dosing of lamivudine in HIV- infected children, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 77(5): 852-860.
  • Piana Chiara, Zhao Wei, Adkison Kimberly, Burger David, Jacqz-Aigrain Evelyne, Danhof Meindert & Della Pasqua Oscar (2014), Covariate effects and population pharmacokinetics of lamivudine in HIVinfected children, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 77(5): 861-872.
  • De Cock R. F. W., Smits A., Allegaert K., de Hoon J., Saegeman V., Danhof M. & Knibbe C. A. J. (2014), Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates, JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 69(5): 1330-1338.
  • Taneja A., Troconiz I. F., Danhof M. & Della Pasqua O. (2014), Semi-mechanistic Modelling of the Analgesic Effect of Gabapentin in the Formalin-Induced Rat Model of Experimental Pain, PHARMACEUTICAL RESEARCH 31(3): 593-606.
  • Krekels E.H.J., Tibboel D., Wildt S.N. de, Ceelie I., Dahan A. Dijk M. van, Danhof M. & Knibbe C.A.J. (2014), Evidence-based morphine dosing for postoperative neonates and infants., Clinical Pharmacokinetics 53(6): 553-563.
  • Mochel Jonathan P., Fink Martin, Peyrou Mathieu, Desevaux Cyril, Deurinck Mark, Giraudel Jerome M. & Danhof Meindert (2013), Chronobiology of the renin-angiotensin-aldosterone system in dogs: relation to blood pressure and renal physiology, CHRONOBIOLOGY INTERNATIONAL 30(9): 1144-1159.
  • Chain Anne S. Y., Dieleman Jeanne P., van Noord Charlotte, Hofman Albert, Stricker Bruno H. Ch, Danhof Meindert, Sturkenboom Miriam C. J. M. & Della Pasqua Oscar (2013), Not-in-trial simulation I: Bridging cardiovascular risk from clinical trials to real-life conditions, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 76(6): 964-972.
  • Reddy Venkatesh Pilla, Kozielska Magdalena, Johnson Martin, Mafirakureva Nyashadzaishe, Vermeulen An, Liu Jing, de Greef Rik, Rujescu Dan, Groothuis Geny M. M., Danhof Meindert & Proost Johannes H. (2013), Population Pharmacokinetic-Pharmacodynamic Modeling of Haloperidol in Patients With Schizophrenia Using Positive and Negative Syndrome Rating Scale, Journal of Clinical Psychopharmacology 33(6): 731-739.
  • Wang Chenguang, Sadhavisvam Senthilkumar, Krekels Elke H. J., Dahan Albert, Tibboel Dick, Danhof Meindert, Vinks Alexander A. & Knibbe Catherijne A. J. (2013), Developmental Changes in Morphine Clearance Across the Entire Paediatric Age Range are Best Described by a Bodyweight-Dependent Exponent Model, Clinical Drug Investigation 33(7): 523-534.
  • Chain Anne S. Y., Dubois Vincent F. S., Danhof Meindert, Sturkenboom Miriam C. J. M. & Della Pasqua Oscar (2013), Identifying the translational gap in the evaluation of drug-induced QT(c) interval prolongation, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 76(5): 708-724.
  • Snelder N., Ploeger B. A., Luttringer O., Rigel D. F., Webb R. L., Feldman D., Fu F., Beil M., Jin L., Stanski D. R. & Danhof M. (2013), PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats, BRITISH JOURNAL OF PHARMACOLOGY 169(7): 1510-1524.
  • Ince Ibrahim, de Wildt Saskia N., Wang Chengueng, Peeters Mariska Y. M., Burggraaf Jacobus, Jacqz-Aigrain Evelyne, van den Anker John N., Tibboel Dick, Danhof Meindert & Knibbe Catherijne A. J. (2013), A Novel Maturation Function for Clearance of the Cytochrome P450 3A Substrate Midazolam from Preterm Neonates to Adults, Clinical Pharmacokinetics 52(7): 555-565.
  • Westerhout Joost, Smeets Jean, Danhof Meindert & de Lange Elizabeth C. M. (2013), The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid, JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 40(3): 327-342.
  • Zhao Wei, Piana Chiara, Danhof Meindert, Burger David, Della Pasqua Oscar & Jacqz-Aigrain Evelyne (2013), Population pharmacokinetics of abacavir in infants, toddlers and children, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 75(6): 1525-1535.
  • Kozielska Magdalena, Reddy Venkatesh Pilla, Johnson Martin, de Ridder Filip, Vermeulen An, Liu Jing, Groothuis Geny M. M., Danhof Meindert & Proost Johannes H. (2013), Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia, SCHIZOPHRENIA RESEARCH 146(1-3): 53-58.
  • Ince Ibrahim, Knibbe Catherijne A. J., Danhof Meindert & de Wildt Saskia N. (2013), Developmental Changes in the Expression and Function of Cytochrome P450 3A Isoforms: Evidence from In Vitro and In Vivo Investigations, Clinical Pharmacokinetics 52(5): 333-345.
  • Reddy Venkatesh Pilla, Kozielska Magdalena, Suleiman Ahmed Abbas, Johnson Martin, Vermeulen An, Liu Jing, de Greef Rik, Groothuis Geny M. M., Danhof Meindert & Proost Johannes H. (2013), Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: Part II: The use of subscales of the PANSS score, SCHIZOPHRENIA RESEARCH 146(1-3): 153-161.
  • Reddy Venkatesh Pilla, Kozielska Magdalena, Suleiman Ahmed Abbas, Johnson Martin, Vermeulen An, Liu Jing, de Greef Rik, Groothuis Geny M. M., Danhof Meindert & Proost Johannes H. (2013), Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: The use of PANSS total score and clinical utility, SCHIZOPHRENIA RESEARCH 146(1-3): 144-152.
  • Mochel J. P., Peyrou M., Fink M., Strehlau G., Mohamed R., Giraudel J. M., Ploeger B. & Danhof M. (2013), Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs, Journal of Veterinary Pharmacology and Therapeutics 36(2): 174-180.
  • Post Teun M., Schmidt Stephan, Peletier Lambertus A., de Greef Rik, Kerbusch Thomas & Danhof Meindert (2013), Application of a mechanism-based disease systems model for osteoporosis to clinical data, JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 40(2): 143-156.
  • Stringer Frances, Ploeger Bart A., DeJongh Joost, Scott Graham, Urquhart Richard, Karim Aziz & Danhof Meindert (2013), Evaluation of the Impact of UGT Polymorphism on the Pharmacokinetics and Pharmacodynamics of the Novel PPAR Agonist Sipoglitazar, The Journal of Clinical Pharmacology 53(3): 256-263.
  • Bartelink Imke Heleen, Belitser Svetlana V., Knibbe Catherijne A. J., Danhof Meindert, de Pagter Anne J., Egberts Toine C. G. & Boelens Jaap Jan (2013), Immune Reconstitution Kinetics as an Early Predictor for Mortality using Various Hematopoietic Stem Cell Sources in Children, Biology of Blood and Marrow Tranplantation 19(2): 305-313.
  • De Cock Roosmarijn F. W., Knibbe Catherijne A. J., Kulo Aida, de Hoon Jan, Verbesselt Rene, Danhof Meindert & Allegaert Karel (2013), Developmental pharmacokinetics of propylene glycol in preterm and term neonates, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 75(1): 162-171.
  • Wang C., Sadhavisvam S., Krekels E.H.J., Dahan A., Tibboel D., Danhof M., Vinks A.A. & Knibbe C.A.J. (2013), Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent model., Clinical Drug Investigation 33(7): 69523-69534.
  • Stevens J., Ploeger B.A., Hammarlund-Udenaes M., Osswald G., Graaf P.H. van der, Danhof M. & Lange E.C.M. de (2012), Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans, Journal of Pharmacokinetics and Pharmacodynamics 39(5): 463-477.
  • Westerhout J, Ploeger B., Smeets J., Danhof M. & Lange E.C.M. de (2012), Physiologically Based Pharmacokinetic Modeling to Investigate Regional Brain Distribution Kinetics in Rats, AAPS JOURNAL 14(3): 543-553.
  • Wang C., Peeters M.Y., Allegaert K., Blussé van Oud-Alblas H.J., Krekels E.H.J., Tibboel D., Danhof M. & Knibbe C.A.J. (2012), A bodyweight-dependent allometric exponent for scaling clearance across the human life-span., PHARMACEUTICAL RESEARCH 29(6): 1570-1581.
  • Krekels E.H.J., Johnson T.N., Hoedt S.M. den, Rostami-Hodjegan A., Danhof M., Tibboel D. & Knibbe C.A.J. (2012), From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part II-Sensitivity to Physiological and Physicochemical Properties., CPT: Pharmacometrics & Systems Pharmacology 2012(1): e10.
  • Krekels E.H.J., Danhof M., Tibboel D. & Knibbe C.A.J. (2012), Ontogeny of hepatic glucuronidation; methods and results., Current Drug Metabolism 13(6): 728-743.
  • Krekels E.H.J., Neely M., Panoilia E., Tibboel D., Capparelli E., Danhof M., Mirochnick M. & Knibbe C.A.J. (2012), From pediatric covariate model to semiphysiological function for maturation: part I-extrapolation of a covariate model from morphine to Zidovudine, CPT: Pharmacometrics & Systems Pharmacology 2012(1): e9.
  • Knibbe C.A. & Danhof M. (2011), Individualized dosing regimens in children based on population PKPD modelling: are we ready for it?, International Journal of Pharmaceutics 415(1-2).
  • Santen G. W., van Zwet E., Bettica P., Gomeni R.A., Danhof M. & Della Pasqua O. (2011), From trial and error to trial simulation III: a framework for interim analysis in efficacy trials with antidepressant drugs, Clinical Pharmacology and Therapeutics 89(4).
  • Piana C., Danhof M. & Della Pasqua O.E. (2011), Impact of Non-Adherence to Antiretroviral Therapy in Hiv-Infected Children, Basic & Clinical Pharmacology & Toxicology 109.
  • Cella M., Zhao W., Jacqz-Aigrain E. M., Burger D., Danhof M. & Della Pasqua O. (2011), Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations?, Br J Clin Pharmacol 72(3).
  • Pilla Reddy V., Kozielska M., Johnson M., Vermeulen A., de Greef R., Liu J., Groothuis G.M., Danhof M. & Proost J.H. (2011), Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders, Clinical Pharmacokinetics 50(7).
  • Wang C.., Peeters M.Y.M., Allegaert K., Tibboel D., Danhof M. & Knibbe C.A.J. (2011), Scaling Clearance of Propofol from Preterm Neonates to Adults, British Journal of Clinical Pharmacology 72(5).
  • Krekels E.H., DeJongh J., van Lingen R.A., van der Marel C.D., Choonara I., Lynn A.M., Danhof M., Tibboel D. & Knibbe C.A. (2011), Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children, Clinical Pharmacokinetics 50(1).
  • Krekels E.H.J., van Hasselt J.G.C., Tibboel D., Danhof M. & Knibbe C.A.J/ (2011), Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models., Pharmaceutical Research 28(4): 797-8911.
  • Stevens J., Ploeger B.A., van der Graaf P.H., Danhof M. & de Lange E.C. (2011), Systemic and Direct Nose-to-Brain Transport Pharmacokinetic Model for Remoxipride after Intravenous and Intranasal Administration, Drug Metabolism and Disposition 39(12).
  • Chain A.S.Y., Dieleman J.P., Danhof M., Stricker B.H.Ch., Della Pasqua O.E. & Sturkenboom M.C.J.M. (2011), Validation of a Not-in-Trial Simulation Tool for Cardiovascular Risk Mitigation, Pharmacoepidemiology and Drug Safety 20.
  • Ackaert O.W., De Graan J., Shi S., Vreeken R., Della Pasqua O.E., Dijkstra D., Westerink B.H., Danhof M. & Bouwstra J.A. (2011), The Pharmacokinetics and Pharmacological Effect of (S)-5-OH-DPAT Following Controlled Delivery with Transdermal Iontophoresis, Journal of Pharmaceutical Sciences 100(7).
  • De Cock R.F.W., Allegaert K., de Hoog M., Sherwin C.M.T., Danhof M. & Knibbe C.A.J. (2011), Predicting Glomerular Filtration Rate Using Clearance of Amikacin in Neonates - Model Evaluation, British Journal of Clinical Pharmacology 72(5).
  • Westerhout J., Danhof M. & de Lange E.C. (2011), Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting, Journal of Pharmaceutical Sciences 100(9).
  • Bartelink I.H., Boelens J.J., Bredius R.G.M., Egberts A.C.G., Bierings M., Shaw P., Hempel G., Zwaveling J., Danhof M. & Knibbe C.A.J. (2011), Modeling of the Age-Related Pharmacokinetics in Children. A Data-Driven Analysis of Busulfan Prior to Haemopoietic Stem Cell Transplantation, British Journal of Clinical Pharmacology 72(5).
  • Danhof M. (2011), Mechanism-Based Pkpd Modeling: Principle and Applications, Basic & Clinical Pharmacology & Toxicology 109.
  • Johnson M., Kozielska M., Reddy V.P., Vermeulen A., Li C., Grimwood S., de Greef R., Groothuis G.M.M., Danhof M. & Proost J.H. (2011), Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of the Dopamine D(2) Receptor Occupancy of Olanzapine in Rats, Pharmaceutical Research 28(10).
  • Bartelink I.H., Jol-van der Zijde E.M., Boelens J.J., Bredius R.G.M., Egberts A.C.G., Danhof M., van Tol MJD & Knibbe C.A.J. (2011), Optimization of Anti-Thymocyte Globulin Exposure in Paedi-Atric Bone Marrow Transplantation in Order to Design an Individualized Dosing Regimen, Biology of Blood and Marrow Tranplantation 17(2).
  • Bartelink I.H., Boelens J.J., Bredius R.G.M., Egberts A.C.G., Biering M., Shaw P., Nath C.E., Hempel G., Zwaveling J., Danhof M. & Knibbe C.A.J. (2011), Optimizing the Busulfan Dosing Regimen to Get a More Predictable Exposure: A Data Driven Analysis, Biology of Blood and Marrow Tranplantation 17(2).
  • van Kralingen S., Diepstraten J., Peeters M.Y., Deneer V.H., van Ramshorst B., Wiezer R.J., Van Dongen E.P., Danhof M. & Knibbe C.A. (2011), Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients, Clinical Pharmacokinetics 50(11).
  • Krekels E.H.J., van Ham S., Allegaert K., de Hoon J., Tibboel D., Danhof M. & Knibbe C.A.J. (2011), Paracetamol Pharmacokinetics in Term and Preterm Neonates, British Journal of Clinical Pharmacology 72(5).
  • Schmidt S., Post T.M., Peletier L.A., Boroujerdi M.A. & Danhof M. (2011), Mathematical Model Reduction: An Innovative Tool for Analyzing Complex Dynamic Disease Systems, Journal Clinical Pharmacology 51(9).
  • Teutonico D., Musuamba F., Maas H.J., Facius A., Yang S., Danhof M. & Della Pasqua O.E. (2011), Multivariate Patient Simulation for Clinical Trial Optimization in Copd, Basic & Clinical Pharmacology & Toxicology 109.
  • Snelder N., Ploeger B., Danhof M., Stanski D., Rigel D., Webb R., Feldman D. & Luttringer O. (2011), Drug Effects on the Cardiovascular System - Development of a Mechanism-Based Pharmacodynamic Model to Improve Translation Drug Research, Clinical Pharmacology & Therapeutics 89.
  • Knibbe C.A.J., Krekels E.H.J. & Danhof M. (2011), Advances in paediatric pharmacokinetics, Expert opinion on drug metabolism & toxicology 7(1): 1-8.
  • Bartelink I.H., Belitser S.V., Knibbe C.A.J., Danhof M., de Pagter A.J., Egberts A.C.G. & Boelens J.J. (2011), Cd3+Cd4+and Cd3+Cd8+-Lymphocytes as Biomarkers Predicting the Long Term Outcome of Pediatric Haematopoietic Stem Cell Transplantation Recipients, Biology of Blood and Marrow Tranplantation 17(2).
  • Bartelink I.H., Belitser S.V., Knibbe C.A.J., Danhof M., de Pagter P.J., Egberts A.C.G. & Boelens J.J. (2011), Cd3+Cd4+-Lymphocytes as Biomarker Predicting the Outcome of Pediatric Haematopoietic Stem Cell Transplantation Recipients, British Journal of Clinical Pharmacology 72(5).
  • Strougo A., Yassen A., Krauwinkel W., Danhof M. & Freijer J. (2011), A semiphysiological population model for prediction of the pharmacokinetics of drugs under liver and renal disease conditions, Drug Metabolism and Disposition 39(7).
  • Chain A.S., Krudys K.M., Danhof M. & Della Pasqua O. (2011), Assessing the Probability of Drug-Induced QTc-Interval Prolongation During Clinical Drug Development, Clinical Pharmacology and Therapeutics 90(6).
  • Ince I., de Wildt S.N., Peeters M.Y.M., Murry D.J., Tibboel D., Danhof M. & Knibbe C.A. (2011), Criticall Illness Is a Major Determinant for Midazolam and Metabolite Clearance in Children, British Journal of Clinical Pharmacology 72(5).
  • Schmidt S., Post T.M., Peletier L.A., Boroujerdi M.A. & Danhof M. (2011), Coping with time scales in disease systems analysis: application to bone remodeling, Journal of Pharmacokinetics and Pharmacodynamics 38(6).
  • Stevens J, van den Berg D.J., de Ridder S., Niederländer H.A., van der Graaf P.H., Danhof M. & de Lange E.C.M. (2010), Online solid phase extraction with liquid chromatography-tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples., J Chromatogr B Analyt Technol Biomed Life Sci 878(13-14): 969-75.
  • Cella M., Gorter de Vries F., Burger D., Danhof M. & Della Pasqua O. (2010), A model-based approach to dose selection in early pediatric development, Clinical Pharmacology and Therapeutics 87(3).
  • Press R.R., Ploeger B.A., Den Hartigh J., van der Straaten T., van Pelt H., Danhof M., de Fijter H. & Guchelaar H.J. (2010), Explaining variability in ciclosporin exposure in adult kidney transplant recipients, European Journal of Clinical Pharmacology 66(6).
  • Bender G., Florian J.A.,Jr., Bramwell S., Field M.J., Tan K.K., Marshall S., DeJongh J., Bies R.R. & Danhof M. (2010), Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain, Journal of Pharmacology and Experimental Therapeutics 334(2).
  • Muller A.E., Mouton J.W., Oostvogel P.M., Dorr P.J., Voskuyl R.A., DeJongh J., Steegers E.A. & Danhof M. (2010), Pharmacokinetics of clindamycin in pregnant women in the peripartum period, Antimicrobial Agents and Chemotherapy 54(5).
  • De Cock R.F., Piana C., Krekels E.H., Danhof M., Allegaert K. & Knibbe C.A. (2010), The role of population PK-PD modelling in paediatric clinical research, European Journal of Clinical Pharmacology.
  • Cella M., Knibbe C. A., Danhof M. & Pasqua O.D. (2010), What is the right dose for children?, Br J Clin Pharmacol 70(4).
  • Della Pasqua O., Santen G.W. & Danhof M. (2010), The missing link between clinical endpoints and drug targets in depression, Trends in Pharmacological Sciences 31(4).
  • Krekels E.H., van Hasselt J.G., Tibboel D., Danhof M. & Knibbe C.A. (2010), Systematic Evaluation of the Descriptive and Predictive Performance of Paediatric Morphine Population Models, Pharm Res.
  • Peeters M.Y., Allegaert K., Blusse van Oud-Alblas H.J., Cella M., Tibboel D., Danhof M. & Knibbe C.A. (2010), Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model, Clinical Pharmacokinetics 49(4).
  • Knibbe C.A., Krekels E.H. & Danhof M. (2010), Advances in paediatric pharmacokinetics, Expert Opin Drug Metab Toxicol 7(1).
  • Post T.M., Cremers S.C., Kerbusch T. & Danhof M. (2010), Bone physiology, disease and treatment: towards disease system analysis in osteoporosis, Clinical Pharmacokinetics 49(2).
  • Romero K., Corrigan B., Tornoe C.W., Gobburu J.V., Danhof M., Gillespie W.R., Gastonguay M.R., Meibohm B. & Derendorf H. (2010), Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success, Journal Clinical Pharmacology 50(9 Suppl).
  • Stevens J., van den Berg D.J., de Ridder S., Niederlander H.A., van der Graaf P.H., Danhof M. & de Lange E.C. (2010), Online solid phase extraction with liquid chromatography-tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples, J Chromatogr B Analyt Technol Biomed Life Sci 878(13-14).
  • Geldof M., Freijer J.L., Beijsterveldt L. van, Langlois X. & Danhof M. (2008), Pharmacokinetic-pharmacodynamic modelling of fluvoxamine 5-HT transporter occupancy in rat frontal cortex, British Journal of Pharmacology 154(6): 1369-1378.
  • Geldof M., Freijer J.L., Peletier L.A., Beijsterveldt L. van & Danhof M. (2008), Mechanistic model for the acute effect of fluvoxamine on 5-HT and 5-HIAA concentrations in rat frontal cortex, European Journal of Pharmaceutical Sciences 33(3): 217-229.
  • Post T.M., Freijer J.L., Ploeger B.A. & Danhof M. (2008), Extensions to the Visual Predictive Check to facilitate model performance evaluation, Journal of Pharmacokinetics and Pharmacodynamics 35(2): 185-202.
  • Geldof M., Freijer J.L., Beijsterveldt L. van & Danhof M. (2008), Pharmacokinetic Modeling of Non-Linear Brain Distribution of Fluvoxamine in the Rat, Pharmaceutical Research 25(4): 792-804.
  • Yassen A., Olofsen E., Kan J., Dahan A. & Danhof M. (2008), Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats., Pharmaceutical Research 25(1): 183-193.
  • Verpoorte R., Crommelin D.J.A., Danhof M., Gilissen L.J., Schuitmaker H., Greef J. van der & Witkamp R.F. (2008), Commentary: "A systems view on the future of medicine: Inspiration from Chinese medicine?", Journal of Ethnopharmacology.
  • Huntjens D.R.H., Strougo A., Chain A., Metcalf A., Summerfield S., Spalding D.J., Danhof M. & Pasqua O.D. (2008), Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats, British Journal of Pharmacology 153(5): 1072-1084.
  • Maas H.J., Spruit M.A., Danhof M. & Della Pasqua O.E. (2008), Relevance of absorption rate and lag time to the onset of action in migraine, Clinical Pharmacokinetics 47(2): 139-146.
  • Ince I., Wildt S.N. de, Tibboel D., Danhof M. & Kribbe C.A. (2008), Tailor-made drug treatment for children Creation of an infrastructure for data-sharing and population PK-PD modeling, Drug Discovery Today.
  • Muller A.E., Jongh J. de, Oostvogel P.M., Voskuyl R.A., Dörr PJ, Danhof M. & Mouton J.W. (2008), Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes, American Journal of Obstetrics and Gynecology 198(1): 1-6.
  • Santen G.W.E., Gomeni R., Danhof M. & Pasqua O.D. (2008), Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy, J. Psychiatr. Res. 42(12): 1000-1009.
  • Maas H.J., Snelder N., Danhof M. & Della Pasqua O.E. (2008), Prediction of attack frequency in migraine treatment, Cephalalgia 28(8): 847-855.
  • Liefaard L.C., Ploeger B.A., Molthoff C.F., Jong H.W. de, Dijkstra J., Weerd L van der, Lammertsma A.A., Danhof M. & Voskuyl R.A. (2008), Changes in GABA(A) receptor properties in amygdala kindled animals: In vivo studies using [(11)C]flumazenil and positron emission tomography, Epilepsia.
  • Muller A.E., Dörr PJ, Mouton J.W., Jongh J. de, Oostvogel P.M., Steegers E.A., Voskuyl R.A. & Danhof M. (2008), The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women, British Journal of Clinical Pharmacology 66(6): 866-874.
  • Peeters M.Y., Aarts L.P., Boom F.A., Bras L.J., Tibboel D., Danhof M. & Knibbe C.A.J. (2008), Pilot study on the influence of liver blood flow and cardiac output on the clearance of propofol in critically ill patients, European Journal of Clinical Pharmacology 64(3): 329-334.
  • Ravenstijn P.G.M., Merlini M., Hameetman M., Murray T.K., Ward M.A., Lewis H., Ball G., Mottart C., Ville de Goyet C. de, Lemarchand T., Belle K. van, O'Neill M.J., Danhof M. & Lange E.C.M. de (2008), The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments, Journal of Pharmacological and Toxicological Methods 57(2): 114-130.
  • Danhof M., Lange E.C.M. de, Della Pasqua O.E., Ploeger B.A. & Voskuyl R.A. (2008), Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research, Trends in Pharmacological Sciences 29(4): 186-191.
  • Groenendaal D., Frijer J., Rosier A., Mik D. de, Nichols G., Hersey A., Ayrton A.D., Danhof M. & Lange E.C. de (2008), Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics, European Journal of Pharmaceutical Sciences 34(2-3): 149-163.
  • Huntjes D.R., Danhof M. & Della Pasqua O.E. (2008), Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors, Rheumatology Oxford 44(7): 846-859.
  • Huntjens D.R.H., Spalding D.J., Danhof M. & Della Pasqua O.E. (2008), Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo-oxygenase inhibitors, European Journal of Pain.
  • Steeg T.J. van, Freijer J.L., Danhof M. & Lange E.C.M. de (2008), Mechanism-based pharmacodynamic modeling of S(-)-Atenolol: Estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model, Journal of Pharmacology and Experimental Therapeutics 324(3): 1234-1342.
  • Clinckers R., Smolders I., Michotte Y., Ebinger G., Danhof M., Voskuyl R.A. & Della Pasqua O.E. (2008), Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain, British Journal of Pharmacology 155(7): 1127-1138.
  • Peeters M.Y., Bras L.J., DeJongh J., Wesselink R.M., Aarts L.P., Danhof M. & Knibbe C.A.J. (2008), Disease Severity Is a Major Determinant for the Pharmacodynamics of Propofol in Critically Ill Patients, Clinical Pharmacology & Therapeutics 83(3): 443-451.
  • Santen G.W.E., Danhof M. & Della Pasqua O.E. (2008), Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model, J. Psychiatr. Res. 42(14): 1189-1197.
  • Muller A.E., Jongh J. de, Bult Y., Goessens W.H., Mouton J.W., Danhof M. & Anker J.N. van den (2007), Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks, Antimicrobial Agents and Chemotherapy 10: 3720-3725.
  • Yassen A., Olofsen E., Kan J., Dahan A. & Danhof M. (2007), Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine., Clinical Pharmacokinetics 46(5): 433-447.
  • Jonker D.M., Voskuyl R.A. & Danhof M. (2007), Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments?, Epilepsia 48(3): 412-434.
  • Liefaard L.C., Gunput R.A., Danhof M. & Voskuyl R.A. (2007), Decreased Efficacy of GABAA-receptor modulation by midazolam in the kainate model of temporal lobe epilepsy, Epilepsia 48(7): 1378-1387.
  • Steeg T.J. van, Freijer J.L., Danhof M. & Lange E.C.M. de (2007), Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint, British Journal of Pharmacology 151(3): 356-366.
  • Geldof M., Freijer J.L., Beijsterveldt L. van, Vermote P.C., Megens A.A. & Danhof M. (2007), Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior, European Journal of Pharmaceutical Sciences 32(3): 200-208.
  • Yassen A., Kan J., Olofsen E., Suidgeest E., Dahan A. & Danhof M. (2007), Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats., Journal of Pharmacology and Experimental Therapeutics 321(2): 598-607.
  • Danhof M., Jongh J. de, Lange J., Della Pasqua O.E., Ploeger B.A. & Voskuyl R.A. (2007), Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling: Biophase Distribution, Receptor Theory, and Dynamical Systems Analysis, Annual Review of Pharmacology and Toxicology 47: 357-400.
  • Yassen A., Olofsen E., Dorp E.L. van, Sarton E.Y., Teppema L.J.S.M., Danhof M. & Dahan A. (2007), Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone: a study in healthy volunteers., Clinical Pharmacokinetics 46(11): 965-980.
  • Groenendaal D., Freijer J.L., Mik D. de, Bouw M.R., Danhof M. & Lange E.C.M. de (2007), Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux, British Journal of Pharmacology 151(5): 701-712.
  • Steeg T.J. van, Krekels E.H., Danhof M. & Lange E.C.M. de (2007), Reproducible and time-dependent modification of serum protein binding in Wistar Kyoto rats, Journal of Pharmacological and Toxicological Methods 56(1): 72-78.
  • Yassen A., Olofsen E., Romberg R., Sarton E.Y., Teppema L.J.S.M., Danhof M. & Dahan A. (2007), Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers., Clinical Pharmacology & Therapeutics 81(1): 50-58.
  • Rolan P., Danhof M., Stanski D. & Peck C. (2007), Current issues relating to drug safety especially with regard to the use of biomarkers: a meeting report and progress update, European Journal of Pharmaceutical Sciences 30(2): 107-112.
  • Groenendaal D., Freijer J.L., Mik D. de, Bouw M.R., Danhof M. & Lange E.C.M. de (2007), Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG, British Journal of Pharmacology 151(5): 713-720.
  • Anisimov V.V., Maas H.J., Danhof M. & Della Pasqua O.E. (2007), Analysis of responses in migraine modelling using hidden Markov models, Statistics in Medicine 26(22): 4163-4178.
  • Zuideveld K.P., Graaf P.H. van der, Peletier L.A. & Danhof M. (2007), Allometric scaling of pharmacodynamic responses: application to 5-Ht1A receptor mediated responses from rat to man, Pharmaceutical Research 24(11): 2031-2039.
  • Freijer J.L., Post T.M., Ploeger B.A., DeJongh J. & Danhof M. (2006), Application of the Convection-Dispersion Equation to Modelling Oral Drug Absorption, Bulletin of Mathematical Biology.
  • Nugroho A.K., Romeijn S.G., Zwier R., Vries J.B. de, Dijkstra D., Wikström H., Pasqua O.D., Danhof M. & Bouwstra J.A. (2006), Pharmacokinetics and pharmacodynamics analysis of transdermal iontophoresis of 5-OH-DPAT in rats: in vitro - in vivo correlation, Journal of Pharmaceutical Sciences 95: 1570-1585.
  • Franciosi L.G., Page C.P., Celli B.R., Cazzola M., Walker M.J., Danhof M., Rabe K.F. & Della Pasqua O.E. (2006), Markers of exacerbation severity in chronic obstructive pulmonary disease, Respiratory Research 7: 74-87.
  • Swart E.L., Zuideveld K.P., Jongh J. de, Danhof M., Thijs L.G. & Strack van Schijndel R.M. (2006), Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients, European Journal of Clinical Pharmacology 62(3): 185-194.
  • Maas H.J., Danhof M. & Della Pasqua O.E. (2006), Prediction of headache response in migraine treatment, Cephalalgia 26: 416-422.
  • Maas H.J., Danhof M. & Della Pasqua O.E. (2006), A model-based approach to treatment comparison in acute migraine, British Journal of Clinical Pharmacology 62(5): 591-600.
  • Peeters M.Y., Prins S.A., Knibbe C.A.J., DeJongh J., Schaik R.H. van, Dijk M van, Heiden I. van der, Tibboel D. & Danhof M. (2006), Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery, Anesthesiology 104(3): 466-474.
  • Franciosi L.G., Page C.P., Celli B.R., Cazzola M., Walker M.J., Danhof M., Rabe K.F. & Della Pasqua O.E. (2006), Markers of disease severity in chronic obstructive pulmonary disease, Pulmonary Pharmacology and Therapeutics 19: 189-199.
  • Geldof M., Freijer J.L., Beijsterveldt L. van, Timmerman P., Ahnaou A., Drinkenburg W.H. & Danhof M. (2006), Population pharmacokinetic model of fluvoxamine in rats: Utility for application in animal behavioral studies, European Journal of Pharmaceutical Sciences 30(1): 45-55.
  • Peeters M.Y., Prins S.A., Knibbe C.A.J., DeJongh J., Mathot R.A.A., Warris C., Schaik R.H. van, Tibboel D. & Danhof M. (2006), Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery, Anesthesiology 105(6): 1135-1146.
  • Winter W. de, DeJongh J., Post T.M., Ploeger B.A., Urquhart R., Moules I., Eckland D. & Danhof M. (2006), A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus, Journal of Pharmacokinetics and Pharmacodynamics 33(3): 313-343.
  • Huntjens D.R.H., Spalding D.J., Danhof M. & Della Pasqua O.E. (2006), Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers, British Journal of Pharmacology 148(4): 396-404.
  • Yassen A., Kan J., Olofsen E., Suidgeest E., Dahan A. & Danhof M. (2006), Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats, Journal of Pharmacology and Experimental Therapeutics 319(2): 682-692.
  • Swart E.L., Jongh J. de, Zuideveld K.P., Danhof M., Thijs L.G. & Strack-van Schijndel R.J.M. (2005), Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration, American Journal of Kidney Diseases 45(2): 360-371.
  • Yassen A., Olofsen E., Dahan A. & Danhof M. (2005), Pharmacokinetic-Pharmacodynamic modelling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics., Journal of Pharmacology and Experimental Therapeutics 313: 1136-1149.
  • Dahan A., Yassen A., Bijl H, Romberg R., Sarton E.Y., Teppema L.J.S.M., Olofsen E. & Danhof M. (2005), Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats, British Journal of Anaesthesia 94(6): 825-834.
  • Schaddelee M.P., Collins S.D., DeJongh J., Boer A.G. de, IJzerman A.P. & Danhof M. (2005), Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and anti-nociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain, European Journal of Pharmaceutical Sciences 514(2-3): 131-140.
  • Schaddelee M.P., Read K.D., Cleypool C.G., IJzerman A.P., Danhof M. & Boer A.G. de (2005), Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents, European Journal of Pharmaceutical Sciences 24(1): 59-66.
  • Nugroho A.K., Li L., Dijkstra D., Wikstrom H., Danhof M. & Bouwstra J.A. (2005), Transdermal iontophoresis of the dopamine agonist 5-OH-DPAT in human skin in vitro, Journal of Controlled Release 103(2): 393-403.
  • Franciosi L.G., Page C.P., Celli B.R., Cazzola M., Walker M.J., Danhof M., Rabe K.F. & Della Pasqua O.E. (2005), Markers of disease severity in chronic obstructive pulmonary disease, Pulmonary Pharmacology and Therapeutics Eprint.
  • Liefaard L.C., Ploeger B.A., Molthoff C.F., Boellaard R., Lammertsma A.A., Danhof M. & Voskuyl R.A. (2005), Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography, Molecular Imaging and Biology 7(6): 411-421.
  • Knibbe C.A.J., Zuideveld K.P., Aarts L.P., Kuks P.F.M. & Danhof M. (2005), Allometric relationships between the pharmacokinetics of propofol in rats, children and adults, British Journal of Clinical Pharmacology 59(6): 705-711.
  • Dahan A., Yassen A., Bijl H, Romberg R., Sarton E.Y., Teppema L.J.S.M., Olofsen E. & Danhof M. (2005), A comparison of the respiratory effects of intravenous buprenorphine and fentanyl in hu, British Journal of Anaesthesia 96: 825-834.
  • Post T.M., Freijer J.L., DeJongh J. & Danhof M. (2005), Disease system analysis: basic disease progression models in degenerative disease, Pharmaceutical Research 22(7): 1038-1049.
  • Nugroho A.K., Danhof M., Bouwstra J.A. & Della Pasqua O.E. (2005), Compartmental modeling of transdermal iontophoretic transport II: in vivo model derivation and application, Pharmaceutical Research 22(3): 335-346.
  • Li G.L., Vries J.J. de, Steeg T.J. van, Bussche H. van den, Maas H.J., Reeuwijk H.J.E.M., Danhof M., Bouwstra J.A. & Laar T. van (2005), Transdermal iontophoretic delivery of apomorphine in patient¿s improved by surfactant formulation pretreatment, Journal of Controlled Release 101: 199-208.
  • Visser C.C., Stevanovic S., Voorwinden L.H., Bloois L. van, Gaillard P.J., Danhof M., Crommelin D.J.A. & Boer A.G. de (2005), Targeting liposomes with protein drugs to the blood-brain barrier in vitro, European Journal of Pharmaceutical Sciences 25(2-3): 299-305.
  • Jonker D.M., Visser S.A.G., Graaf P.H. van der, Voskuyl R.A. & Danhof M. (2005), Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo, Pharmacology and Therapeutics 106(1): 1-18.
  • Groenendaal D., Blom-Roosemalen M.C.M., Danhof M. & Lange E.C.M. de (2005), High-performance liquid chromatography of nalbuphine, butorphanol and morphine in blood and brain microdialysate samples: application to pharmacokinetic/pharmacodynamic studies in rats, Journal of Chromatography. B, Analytical technologies in the biomedical and life sciences 822(1-2): 230-237.
  • Li G.L., Steeg T.J. van, Putter H., Spek J. van der, Pavel S., Danhof M. & Bouwstra J.A. (2005), Cutaneous side-effects of transdermal iontophoresis with and without surfactant pretreatment: a single-blinded, randomized controlled trial, British Journal of Dermatology 153(2): 404-412.
  • Li G.L., Steeg T.J. van, Putter H., Spek J. van der, Pavel S., Danhof M. & Bouwstra J.A. (2005), Cutaneous side-effects of transdermal iontophotresis with and without surfactant pretreatment: a single-blinded, randomized controlled trial., British Journal of Dermatology 153: 404-412.
  • Danhof M., Alvan G., Dahl S.G., Kuhlmann J. & Paintaud G. (2005), Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers, Pharmaceutical Research 22(9): 1432-1437.
  • Yassen A., Olofsen E., Dahan A. & Danhof M. (2005), Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics, Journal of Pharmacology and Experimental Therapeutics 313(3): 1136-1149.
  • Prins S.A., Peeters M.Y., Houmes R.J., Dijk M van, Knibbe C.A.J., Danhof M. & Tibboel D. (2005), Propofol 6% as sedative in children under 2 years of age following major craniofacial surgery, British Journal of Anaesthesia 94(5): 630-635.
  • Nugroho A.K., Li L., Dijkstra D., Wikstrom H., Danhof M. & Bouwstra J.A. (2005), Transdermal iontophoresis of the dopamine agonist 5-OH-DPAT in human skin in vitro. J Control Release, Journal of Controlled Release 21(2): 393-403.
  • Jonker D.M., Visser S.A.G., Graaf P.H. van der, Voskuyl R.A. & Danhof M. (2005), Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo, Pharmacology and Therapeutics 106(1): 1-18.
  • Visser C.C., Stevanovic S., Voorwinden L.H., Gaillard P.J., Crommelin D.J.A., Danhof M. & Boer A.G. de (2004), Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro, Journal of Drug Targeting 12: 145-150.
  • Visser C.C., Voorwinden L.H., Crommelin D.J.A., Danhof M. & Boer A.G. de (2004), Characterization and Modulation of the Transferrin Receptor on Brain Capillary Endothelial Cells, Pharmaceutical Research 21: 761-769.
  • Swart E.L., Zuideveld K.P., Jongh J. de, Danhof M. & Thijs L.G. (2004), Population pharmacokinetics of lorazepam and midazolam in ICU patients after long-term continuous infusion, British Journal of Clinical Pharmacology 57(2): 135-145.
  • Schaddelee M.P., DeJongh J., Collins S.D., Boer A.G. de, IJzerman A.P. & Danhof M. (2004), Population pharmacokinetic-pharmacodynamic modelling of the anti-hyperalgesic effect of 5'deoxy-N6-cylopentyladenosine in the mononeuropathic rat, European Journal of Pharmacology 504: 7-15.
  • Li G.L., Vries J.J. de, Steeg T.J. van, Bussche H. van den, Maas H.J., Reeuwijk H.J.E.M., Danhof M., Bouwstra J.A. & Laar T. van (2004), Transdermal iontophoretic delivery of apomorphine in patients inproved by sufactant formulation pretreatment, Journal of Controlled Release 101: 199-208.
  • Knibbe C.A.J., Naber H., Aarts L.P.H.J., Kuks P.F.M. & Danhof M. (2004), Long-term sedation with propofol 60 mg/ml versus Propofil 10 mg/ml in critically ill, mechanically ventilated patients, Acta Anaesthesiologica Scandinavica 48: 302-307.
  • Schaddelee M.P., Groenendaal D., DeJongh J., Cleypool C.G., IJzerman A.P., Boer A.G. de & Danhof M. (2004), Population pharmacokinetic modeling of blood-brain barrier transport of synthetic adenosine A1 receptor agonists, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 311: 1138-1146.
  • Nugroho A.K., Li G.L., Danhof M. & Bouwstra J.A. (2004), Transdermal iontophoresis of rotigotine across human stratum corneum in vitro: influence of pH and NaCI concentration, Pharmaceutical Research 21: 844-850.
  • Nugroho A.K., Pasqua O.D., Danhof M. & Bouwstra J.A. (2004), Compartmental modeling of transdermal iotophoretic transport: I. In vitro Model derivation and application, Pharmaceutical Research 21: 1974-1984.
  • Zuideveld K.P., Graaf P.H. van der, Newgreen D., Thurlow R., Petty N., Jordan P., Peletier L.A. & Danhof M. (2004), Mechanism-based pharmacokinetic/pharmacodynamic modeling of 5-HT1A receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body termperature in rats, Journal of Pharmacology and Experimental Therapeutics 308: 1012-1020.
  • Jonker D.M., Voskuyl R.A. & Danhof M. (2004), Pharmacodynamic analysis of the anticonvulsant effects of tiagabine and lamotrigine in combination in the rat, Epilepsia 45: 424-435.
  • Danhof M., Graaf P.H. van der, Visser S.A.G. & Zuideveld K.P. (2004), Mechanism-based pharmacodynamic modelling for prediction of exposure response. In: D'Argenio D.Z. (Red.) Advanced Methods of Pharmacokinetic & Pharmacodynamic Systems Analysis. Boston: Kluwer Academic Publishers. 49-65.
  • Swart E.L., Zuideveld K.P., DeJongh J., Danhof M., Thijs L.G. & Strack van Schijndel R.M. (2004), Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients, British Journal of Clinical Pharmacology 57: 135-145.
  • Nugroho A.K., Della Pasqua O.E., Danhof M. & Bouwstra J.A. (2004), Compartmental modeling of transdermal iontophoretic transport: I. In vitro model derivation and application, Pharmacological Research 21: 1974-1984.
  • Nugroho A.K., Li G.L., Danhof M. & Bouwstra J.A. (2004), Transdermal iontophoresis of rotigotine across human stratum corneum in vitro: influence of pH and NaCI concentration, Pharmaceutical Research 21: 844-850.
  • Visser S.A.G., Graaf P.H. van der, Danhof M. & Peletier L.A. (2003), Mechanism-Based Modeling of the Pharmacodynamic Interaction of Alphaxalone and Midazolam in Rats, Journal of Pharmacology and Experimental Therapeutics 307: 765-775.
  • Visser S.A.G., Wolters F.L.C., Gubbens-Stibbe J.M., Tukker E., Graaf P.H. van der, Peletier L.A. & Danhof M. (2003), Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations, Journal of Pharmacology and Experimental Therapeutics 304(1): 88-101.
  • Jonker D.M., Vermeij D.A.C., Edelbroek P.M., Voskuyl R.A., Piotrovsky V.K. & Danhof M. (2003), Pharmacodynamic Analysis of the Interaction between Tiagabine and Midazolam with an Allosteric Model that Incorporates Signal Transduction, Epilepsia 44: 329-338.
  • Schaddelee M.P., Voorwinden H.L., Groenendaal D., Hersey A., IJzerman A.P., Danhof M. & Boer A.G. de (2003), Blood-Brain Barrier transport of Synthetic adenosine A1 receptor agonists in vitro: structure transport relationships, European Journal of Pharmaceutical Sciences 20: 347-356.
  • Li G., Danhof M., Frederik P.M. & Bouwstra J.A. (2003), Pretreatment with a water-based surfactant formulation affects transdermal iontophoretic delivery of R-apomorphine in vitro, Pharmaceutical Research 20(4): 653-659.
  • Visser S.A.G., Gubbens-Stibbe J.M., Graaf P.H. van der, Danhof M. & Peletier L.A. (2003), Mechanism-based Pharmacokinetic/Pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in viro-in vivi modulators, Journal of Pharmacology and Experimental Therapeutics 304: 88-101.
  • Jonker D.M., Mheen C. van de, Eilers P.H.C., Kruk A.R., Voskuyl R.A. & Danhof M. (2003), Anticonvulsant drugs differentially suppress individual ictal signs: A pharmacokinetic/pharmacodynamic analysis in the cortical stimulation model in the rat, Behavioral Neuroscience 117(5): 1076-1085.
  • Bueters T.J.H., Joosen M.J.A., Helden H.P.M., IJzerman A.P. & Danhof M. (2003), Adenosine A1 receptor agonist N6-cyclopentyladenosine affects the inactivation of acetylcholinesterase in blood and brain by sarin, Journal of Pharmacology and Experimental Therapeutics 304: 1307-1313.
  • Li G.L., Grossklaus A., Danhof M. & Bouwstra J.A. (2003), Iontophoric R-apomorphine delivery in combination with surfactant pretreatment: in vitro validation studies, International Journal of Pharmaceutics 266: 61-68.
  • Bueters T.J.H., Duivenvoorde L.M. van, Danhof M., IJzerman A.P. & Helden H.P. van (2003), Cyclopentyladenosine and some of its low-efficacy derivatives inhibit striatal synaptosomal release of acetylcholine to a similar degree, European Journal of Pharmacology 481: 141-146.
  • Bueters T.J.H., Helden H.P. van, IJzerman A.P. & Danhof M. (2003), Low efficacy adenosine A1 agonists inhibit striatal acetylcholine release in rats improving central selectivity of action, Neuroscience Letters 343: 57-61.
  • Schaddelee M.P., Voorwinden H.L., Tilburg E.W. van, Pateman T.J., IJzerman A.P., Danhof M., Soudijn W. & Wijngaarden I. van (2003), Medicinal chemistry of adenosine A1 receptor ligands, Current Topics in Medicinal Chemistry 3: 355-367.
  • Visser S.A.G., Wolters F.L.C., Graaf P.H. van der, Peletier L.A. & Danhof M. (2003), Dose-Dependent EEG Effects of Zolpidem Provide Evidence for GABAA Receptor Subtype Selectivity in Vivo, Journal of Pharmacology and Experimental Therapeutics 304: 1251-1257.
  • Li G.L., Danhof M., Frederik P.M. & Bouwstra J.A. (2003), Pretreatment of water-based surfactant affects transdermal iontophoretic delivery of R-apomorphine in vitro, Pharmaceutical Research 20: 653-659.
  • Bueters T.J.H., IJzerman A.P., Helden H.P.M. & Danhof M. (2003), Characterization of the pharmacokinetics, brain distribution, and therapeutic efficacy of the adenosine A1 receptor partial agonist 2'-deoxy-N6-cyclopentyladenosine in sarin-poisoned rats, Toxicology and Applied Pharmacology 192: 86-94.
  • Knibbe C.A.J., Melenhorst-de Jong G., Mestrom M., Rademaker C.M.A., Reijnvaan A.F.A., Zuideveld K.P., Kuks P.F.M., Vught H. van & Danhof M. (2002), Pharmacokinetic and effects of propofol 6% for short-term sedation in paediatric patients following cardiac Surgery, Br. J. Clin. Pharmacol. 54: 415-422.
  • Zuideveld K.P., Rusic-Pavletic J., Maas J., Peletier L.A., Graaf P.H. van der & Danhof M. (2002), Pharmacokinetic-Pharmacodynamic modeling of buspirone and its metabolite 1-(2-Pyrimidinyl)-Piperazine in rats, Journal of Pharmacology and Experimental Therapeutics 303: 1130-1137.
  • Tuk B., Gool T. & Danhof M. (2002), Mechanism-based pharmacodynamic modelling of the interaction of midazolam, bretazenil and zolpidem with ethano, Journal of Pharmacokinetics and Pharmacodynamics 29: 235-250.
  • Bueters T.J.H., Helden H.P.M., Danhof M. & IJzerman A.P. (2002), Effects of the adenosine A1 receptor allosteric modulators PD81,723 and LUF5484 on the striatal acetylcholine release, European Journal of Pharmacology 454: 177-182.
  • Bueters T.J.H., Groen B., Danhof M., IJzerman A.P. & Helden H.P.M. (2002), Therapeutic efficacy of the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) against organophosphate intoxication, Archives of Toxicology 76: 650-656.
  • Danhof M. & Visser S.A.G. (2002), Pharmaco-encephalography and pharmacokinetic-pharmacodynamic modelling: focus on pre-clinical steps, Methods and Findings in Experimental and Clinical Pharmacology 24: 127-128.
  • Knibbe C.A.J., Zuideveld K.P., Jongh J. de, Kuks P.F.M., Aarts L.L.P. & Danhof M. (2002), Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: A comparison between propofol 6% and propofol 1%, Clinical Pharmacology & Therapeutics 72: 670-684.
  • Visser S.A.G., Smulders J.G.M., Reijers B.P.R., Graaf P.H. van der, Peletier L.A. & Danhof M. (2002), Mechanism-based pharmacokinetic-pharmacodynamic modelling of concentration-dependent hysteresis and biphasic electroencephalogram effects of alphaxalone in rats, Journal of Pharmacology and Experimental Therapeutics 302: 1158-1167.
  • Visser S.A.G., Gladdines W.W.F.T., Graaf P.H. van der, Peletier L.A. & Danhof M. (2002), Neuroactive steroids differ in potency but not in intrinsic efficacy at the GABAA receptor in vivo, Journal of Pharmacology and Experimental Therapeutics 303: 616-626.
  • Lange E.C.M. de & Danhof M. (2002), Considerations in the Use of Cerebrospinal Fluid Pharmacokinetics to Predict Brain Target Concentrations in the Clinical Setting; Implications of the Barriers between Blood and Brain, Clinical Pharmacokinetics 41: 691-703.
  • Li G.L., Geest R. van der, Chanet L., Zanten E. van, Danhof M. & Bouwstra J.A. (2002), In vitro iontophoresis of R-apomorphine across human stratum corneum. Structure-transport relationship of penetration enhancement, Journal of Controlled Release 7: 49-57.
  • Danhof M. (2002), Electroencephalography parameters as biomarkers: extrapolation from laboratory animals to humans, Methods and Findings in Experimental and Clinical Pharmacology 24: 63-64.
  • Li G.L., Geest R. van der, Chanet L., Zanten E. van, Danhof M. & Bouwstra J.A. (2002), In itro iontophoresis of R-apomorphine across human stratum corneum. Structure-transport relationship of penetration enhancement, Journal of Controlled Release 84: 49-57.
  • Zuideveld K.P., Treijtel N., Maas H.J., Gubbens-Stibbe J.M., Peletier L.A., Graaf P.H. van der & Danhof M. (2002), A competitive interaction model predicts the effect of WAY-100,635 on the Time Course of R-(+)-8-Hydroxy-2-(di-n-propylamino)tetralin-Induced Hypothermia, Journal of Pharmacology and Experimental Therapeutics 300: 330-338.
  • Zuideveld K.P., Gestel A. van, Peletier L.A., Graaf P.H. van der & Danhof M. (2002), Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A-receptor agonist flesinoxan, European Journal of Pharmacology 445: 43-54.
  • Swart E.L., Hoven B. van der, Groeneveld A.B.J., Touw D.J. & Danhof M. (2002), Correlation between midazolam and lidocaine pharmacokinetics and EMGX formulation in healthy volunteers, Br. J. Clin. Pharmacol. 53: 133-139.
  • Cleton A., Greef H.J.J.M., Edelbroek P.M., Voskuyl R.A. & Danhof M. (1999), Stereoselective central nervous system effects of the R- and S- isomers of the GABA uptake blocker N-(4,4-di-(3-methylthien-2-yl)but-3-enyl) nipecotic acid in the rat., British Journal of Pharmacology 128: 1651-1658.
  • Cox E.H., Langemeijer M.W.E., Gubbens-Stibbe J.M., Muir K.T. & Danhof M. (1999), The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model, Anesthesiology.
  • Tuk B., Oostenbruggen M.F. van, Herben V.M.M., Mandema J.W. & Danhof M. (1999), Characterization of the pharmacodynamic interaction between parent drug and metabolite: midazolam and a-OH-midazolam, Journal of Pharmacology and Experimental Therapeutics.
  • Graaf P.H. van der, Nilsson J., Schaick E.A. van & Danhof M. (1999), Multivariate quantitative structure-pharmacokinetic relationships (QSPKR) analysis of adenosine A1 receptor agonists in rat, Journal of Pharmaceutical Sciences 88: 306-312.
  • Cleton A., Graaf P.H. van der, Ghijsen W., Voskuyl R.A. & Danhof M. (1999), Mechanism-based modeling of adaptive changes in the pharmacodynamics of midazolam in the kindling model of epilepsy, Pharmaceutical Research 16: 1702-1709.
  • Cleton A., Mazee D., Voskuyl R.A. & Danhof M. (1999), Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats, British Journal of Pharmacology 127: 227-235.
  • Cleton A., Mazee D., Voskuyl R.A. & Danhof M. (1999), Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats, British Journal of Pharmacology 126.
  • Laar T. van, Geest R. van der, Danhof M., Goossens P.H. & Roos R.A.C. (1998), Stepwise intravenous infusion of apomorphine to determine the therapeutic window of patients with Parkinson's disease., Clinical Neuropharmacology 21: 152-158.
  • Geest R. van der, Danhof M. & Boddé H.E. (1998), Validation and testing of a new iontophoretic continuous flow through transport cell, Journal of Controlled Release 51: 85-91.
  • Laar T. van, Geest R. van der, Danhof M., Bodde H.E., Goossens P.H. & Roos R.A. (1998), Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease., Clinical Neuropathology 21: 152-158.
  • Cox E.H., Kuipers J.A. & Danhof M. (1998), Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation, British Journal of Pharmacology 124: 1534-1540.
  • Della Paschoa O.E., Mandema J.W., Voskuyl R.A. & Danhof M. (1998), Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effect of phenytoin in rats, Journal of Pharmacology and Experimental Therapeutics 284(2): 460-466.
  • Della Paschoa O.E., Kruk M.R., Hamstra R., Voskuyl R.A. & Danhof M. (1998), Pharmacodynamic interaction between phenytoin and sodium valproate changes seizure thresholds and pattern., British Journal of Pharmacology 125: 997-1004.
  • Della Paschoa O.E., Madema J.W., Voskuyl R.A. & Danhof M. (1998), Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and eletroencephalogram effects of the phenitoin in rats, Journal of Pharmacology and Experimental Therapeutics 284: 460-466.
  • Cox E.H., Kerbusch Th., Graaf P.H. van der & Danhof M. (1998), Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the m-opioid receptor, Journal of Pharmacology and Experimental Therapeutics 284(3): 1095-1103.
  • Laar T. van, Geest R. van der, Danhof M., Boddé H.E., Goossens P.H. & Roos R.A.C. (1998), Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease, Clinical Neuropharmacology 21(3): 152-158.
  • Della Paschoa O.E., Kruk M.R. & Danhof M. (1998), Pharmacokinetic-pharmacodynamic modelling of behavioural responses., Neuroscience & Biobehavioral Reviews 23: 229-236.
  • Della Paschoa O.E., Kruk M.R., Hamstra R., Voskuyl R.A. & Danhof M. (1998), Pharmacodynamic interaction between phenytoin and sodium valproate changes seizure threshold and pattern, British Journal of Pharmacology 125: 997-1004.
  • Della Paschoa O.E., Voskuyl R.A. & Danhof M. (1998), Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate, British Journal of Pharmacology 125: 1610-1616.
  • Della Paschoa O.E., Kruk M.R., Voskuyl R.A. & Danhof M. (1998), Effects of repeated seizure induction on seizure activity, post-ictal and interictal behavior., Brain Research Bulletin 814: 199-208.
  • Della Paschoa O.E., Kruk M.R., Voskuyl R.A. & Danhof M. (1998), Effects of repeated siezure induction on seizure activity, post-ictal and nterictal behavior, Brain Research Bulletin 814: 199-208.
  • Cox E.H., Knibbe C.A.J., Koster V.S., Langemeijer M.W.E., Tukker H.J., Lange R., Kuks P.F.M., Langemeijer H.J.M., Lie-A-Huen L. & Danhof M. (1998), Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol, Pharmacological Research 15(3): 442-448.
  • Graaf P.H. van der, Schaick E.A. van, Visser S.A.G., Greef H.J.M.M. de, IJzerman A.P. & Danhof M. (1998), Mechanism-based pharmacokinetic-pharmacodynamic modeling of anti-lipolytic effects of adenosine A1 receptor agonists in rats: prediction of tissue-dependent efficay in vivo, Journal of Pharmacology and Experimental Therapeutics.
  • Schaick E.A. van, Zuideveld K.P., Tukker H.J., Langemeijer M.W.E., IJzerman A.P. & Danhof M. (1998), Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adeno-sine in diabetic Zucker rats; influence of the disease on the selectivity of action., Journal of Pharmacology and Experimental Therapeutics 287: 21-30.
  • Cleton A., Voskuyl R.A. & Danhof M. (1998), Adaptive changes in the pharmacodynamics of midazolam in different experimental models of epilepsy: kindling, cortical stimulation and genetic absence epilepsy, British Journal of Pharmacology 125: 615-620.
  • Geest R. van der, Laar T. van, Kruger P.P., Gubbens-Stibbe J.M., Bodde H.E., Roos R.A.C. & Danhof M. (1998), Pharmacokinetics, enantiomer interconversion and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease., Clinical Neuropharmacology 21: 159-168.
  • Cox E.H., Langemeijer M.W.E. & Danhof M. (1998), Pharmacokinetic-pharmacodynamic modelling of the analgesic effect of alfentanil in the rat using tooth pulp evoked potentials, Journal of Pharmacological and Toxicological Methods 39: 19-27.
  • Danhof M., Geest R. van der, Laar T. van & Boddé H.E. (1998), An integrated pharmacokinetic-pharmacodynamic approach to optimization of R-apomorphine delivery in Parkinson's disease, Advanced Drug Delivery Reviews 33: 253-263.
  • Knibbe C.A.J., Voortman H.-J., Aarts L.P.H.J., Kuks P.F.M., Lange R., Langemeijer H.J.M. & Danhof M. (1998), Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN versus propofol 1% SAZN and diprivan®-10 after bolus injection, British Journal of Clinical Pharmacology.
  • Sandt I.C.J. van der, Boer A.G. de, Danhof M. & Breimer D.D. (1998), Selectivity of P-glycoprotein substrates rhodamine-123 and doxorubicin in wild-type and MDR1 cDNA transfected LLC-PK1 cells, British Journal of Pharmacology: 130P.
  • Schaick E.A. van, Tukker H.J., Roelen H.C.P.F., IJzerman A.P. & Danhof M. (1998), Selectivity of action of 8-alkylamino analogues of N6-cyclopentyladenosine in vivo: hemodynamic versus anti-lipolytic responses in rats., British Journal of Pharmacology 124: 607-618.
  • Tuk B., Herben V.M.M., Mandema J.W. & Danhof M. (1998), Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modelling of midazolam, Journal of Pharmacology and Experimental Therapeutics 284(1): 202-207.
  • Schaick E.A. van, Greef H.J.M.M. de, IJzerman A.P. & Danhof M. (1998), Physiological indirect effect modeling of the antilipolytic effects of adenosine A1-receptor agonists, Journal of Pharmacokinetics and Biopharmaceutics 25(6): 673-694.
  • Snoeck H.J.M., Donck K. ver, Jacqmin P., Belle H. van, Dupont A.G., Peer A. van & Danhof M. (1998), Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazine, Journal of Pharmacology and Experimental Therapeutics 286: 142-149.
  • Cleton A., Voskuyl R.A. & Danhof M. (1998), Adaptive changes in the pharmacodynamics of midazolam in different experimental models of epilepsy: kindling, cortical stimulation and genetic absence epilepsy, British Journal of Pharmacology 125: 615-620.
  • Cleton A., Greef H.J.M.M. de, Edelbroek P.M., Voskuyl R.A. & Danhof M. (1998), Application of a combined "effect compartment/indirect response model" to the nervous system effects of tiagabine in the rat, Journal of Pharmacokinetics and Biopharmaceutics.
  • Lange E.C.M. de, Danhof M., Boer A.G. de & Breimer D.D. (1997), Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier, Brain research reviews 25(1): 27-49.
  • Geest R. van der, Laar T. van, Gubbens-Stibbe J.M., Bodde H.E. & Danhof M. (1997), Iontophoretic delivery of R-apomorphine: an in vivo study in patients with Parkinson's disease., Pharmaceutical Research 14: 1803-1809.
  • Della Paschoa O.E., Kruk M.R., Hamstra R., Voskuyl R.A. & Danhof M. (1997), Seizure patterns in kindling and cortical stimulation models of experimental epilepsy., Brain Research 770: 221-227.
  • Della Paschoa O.E., Kruk M.R., Voskuyl R.A., Danhof M. & Hamstra R. (1997), Seizure patterns in kindling and cortical stimulation models of experimental epilepsy, Brain Research Bulletin 770: 221-227.
  • Geest R. van der, Kruger P.P., Gubbens-Stibbe J.M., Laar T. van, Bodde H.E. & Danhof M. (1997), Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronade and sulphate conjugates in plasma and urine of patients with Parkinson's disease., Journal of Chromatography B 702: 131-141.
  • Lange E.C.M. de, Danhof M., Zurcher C., Boer A.G. de & Breimer D.D. (1995), REPEATED MICRODIALYSIS PERFUSIONS - PERIPROBE TISSUE-REACTIONS AND BBB PERMEABILITY, BRAIN RESEARCH 702(1-2): 261-265.
  • Lange E.C.M. de, Bouw M.R., Mandema J.W., Danhof M. Boer A.G. de & Breimer D.D. (1995), Application of intracerebral microdialysis to study regional distribution kinetics of drugs in rat-brain, British Journal of Pharmacology 116(5): 2538-2544.
  • Lange E.C.M. de, Danhof M., Boer A.G. de & Breimer D.D. (1994), CRITICAL FACTORS OF INTRACEREBRAL MICRODIALYSIS AS A TECHNIQUE TO DETERMINED THE PHARMACOKINETICS OF DRUGS IN RAT-BRAIN, BRAIN RESEARCH 666(1): 1-8.
Vakpublicaties
  • Westerhout J., van den Berg D.J., Hartman R., Danhof M. & de Lange E.C. (2014), Prediction of methotrexate CNS distribution in different species - influence of disease conditions., European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2014(Jan 22): 0928-0987.
  • Krekels E.H.J., DeJongh J., Lingen R.A. van, Marel C.D. van der, Choonara I., Lynn A.M., Danhof M., Tibboel D. & Knibbe C.A.J. (2011), Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children., 50(1): 51-63.
  • Cock R.F. de, Piana C., Krekels E.H.J., Danhof M., Allegaert K. & Knibbe C.A.J. (2011), The role of population PK-PD modelling in paediatric clinical research., European Journal of Clinical Pharmacology 67(Suppl 1): 5-16.
  • Steeg T.J. van, Krekels E.H.J., Freijer J., Danhof M. & Lange E.C.M. de (2010), Effect of altered AGP plasma binding on heart rate changes by S(-)-propranolol in rats using mechanism-based estimations of in vivo receptor affinity (K(B,vivo))., Journal of Pharmaceutical Sciences 99(5): 2511-20.
  • Knibbe C.A.J., Krekels E.H.J., Anker J.N. van den, DeJongh J., Santen G.W., Dijk M. van, Simons S.H., Lingen R.A. van, Jacqz-Aigrain E.M., Danhof M. & Tibboel D. (2009), Morphine glucuronidation in preterm neonates, infants and children younger than 3 years., Clinical Pharmacokinetics 48(6): 371-85.
  • Steeg T.J. van, Boralli V.B., Krekels E.H.J., Slijkerman P., Freijer J., Danhof M. & Lange E.C.M. de (2009), Influence of plasma protein binding on pharmacodynamics: Estimation of in vivo receptor affinities of beta blockers using a new mechanism-based PK-PD modelling approach., Journal of Pharmaceutical Sciences 98(10): 3816-28.
  • Steeg T.J. van, Krekels E.H.J., Danhof M. & Lange E.C.M. de (2007), Reproducible and time-dependent modification of serum protein binding in Wistar Kyoto rats., Journal of Pharmacological and Toxicological Methods 56(1): 72-8.
  • Yassen A., Kan J., Olofsen E., Suidgeest E., Dahan A. & Danhof M. (2006), Mechanism based pharmacokinetic/pharmacodynamic modelling of the respiratory depressant effects of buprenorphine in rats, Journal of Pharmacology and Experimental Therapeutics 319: 682-692.
  • Bijl H, Yassen A., Olofsen E., Teppema L.J.S.M., Danhof M. & Dahan A. (2006), Full reversal of buprenorphine-induced respiratory depression by the opioid receptor antagonist naloxone, Nederlands Tijdschrift voor Anesthesiologie 19: 58-64.
  • Yassen A., Olofsen E., Bijl H, Romberg R., Sarton E.Y., Danhof M. & Dahan A. (2006), Mechanism-based pharmacokinetic/pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers, Anesthesiology 104: 1232-1242.
  • Dahan A., Yassen A., Romberg R., Sarton E.Y., Teppema L.J.S.M., Olofsen E. & Danhof M. (2006), Buprenorphine induces ceiling in respiratory depression but not in analgesia, British Journal of Anaesthesia 96(5): 627-632.
  • Dorp E.L. van, Yassen A., Sarton E.Y., Romberg R., Olofsen E., Teppema L.J.S.M., Danhof M. & Dahan A. (2006), Naloxone reversal of buprenorphine-induced respiratory depression, Anesthesiology 105(1): 51-57.
Populariserend
  • Cleton A., Greef H.J.M.M. de, Edelbroek P.M., Voskuyl R.A. & Danhof M. (1998), Pharmacokinetic-pharmacodynamic modeling of the EEG-effect of the GABA uptake inhibitors R- and S-tiagabine. In: Danhof M., Steimer J.L. (Red.) Measurement and kinetics of in vivo drug effects. Advances in simultaneous pharmacokinetic/pharmacodynamic modelling. Leiden: LACDR. 143-145.
  • Cleton A., Graaf P.H. van der, Voskuyl R.A. & Danhof M. (1998), Mechanism-based modelling of the adaptive changes in the pharmacodynamics of midazolan in rats with experimentally induced epilepsy. In: Danhof M., Steimer J.L. (Red.) Measurements and kinetics of in vivo drug effects. Advances in simultaneous pharmacokinetic pharmacodynamic modelling. Leiden: LACDR.
Overig
  • Gotta V., Cools F., van Ammel K., Gallacher D.J., Visser S.A., Sannajust F., Morissette P., Danhof M. & van der Graaf P.H. (2014), Sensitivity of pharmacokinetic-pharmacodynamic analysis for detecting small magnitudes of QTc prolongation in preclinical safety testing, Journal of Pharmacological and Toxicological Methods 72C: 1-10.
  • Stringer F., DeJongh J., Enya K., Koumura E., Danhof M. & Kaku K. (2014), Evaluation of the Long-Term Durability and Glycemic Control of Fasting Plasma Glucose and Glycosylated Hemoglobin for Pioglitazone in Japanese Patients with Type 2 Diabetes, diabetes-technology-and-therapeutics.
  • Mochel J.P., Fink M., Peyrou M., Soubret A., Giraudel J.M. & Danhof M. (2014), Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs, Pharm Res.
  • Wang C., Allegaert K., Peeters M.Y., Tibboel D., Danhof M. & Knibbe C.A. (2014), The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults, Br J Clin Pharmacol 77(1): 149-59.
  • Wang C., Allegaert K., Tibboel D., Danhof M., Marel C.D. van der, Mathot R.A. & Knibbe C.A. (2013), Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults., The Journal of Clinical Pharmacology .
  • Cock R.F. de, Allegaert K., Vanhaesebrouck S., Hoon J. de, Verbesselt R., Danhof M. & Knibbe C.A. (2013), Low but Inducible Contribution of Renal Elimination to Clearance of Propylene Glycol in Preterm and Term Neonates, Therapeutic Drug Monitoring.
  • Stringer F., DeJongh J., Scott G. & Danhof M. (2014), A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar, Br J Clin Pharmacol 54(4): 453-61.
  • Stringer F., Dejongh J., Scott G. & Danhof M. (2013), A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar, Br J Clin Pharmacol 54(4): 453-61.
  • Piana C., Zhao W., Adkison K., Burger D., Jacqz-Aigrain E., Danhof M. & Della Pasqua O. (2013), Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children, Br J Clin Pharmacol.
  • Piana C., Zhao W., Adkison K., Burger D., Jacqz-Aigrain E., Danhof M. & Della Pasqua O. (2013), A model-based approach for the evaluation of once daily dosing of lamivudine in HIV-infected children, British Journal of Clinical Pharmacology.
  • De Cock R.F., Allegaert K., Sherwin C.M., Nielsen E.I., de Hoog M., van den Anker J.N., Danhof M. & Knibbe C.A. (2014), A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates, Pharmacological Research 31(3): 754-67.
  • Visser S.A., Manolis E., Danhof M. & Kerbusch T. (2013), Modeling and simulation at the interface of nonclinical and early clinical drug development, CPT: Pharmacometrics & Systems Pharmacology .
  • Visser S.A., Manolis E., Danhof M. & Kerbusch T. (2013), Modeling and simulation at the interface of nonclinical and early clinical drug development, CPT: Pharmacometrics & Systems Pharmacology 2(2).
  • Taneja A., Troconiz I.F., Danhof M. & Della Pasqua O.; neuropathic pain project of the PKPD modelling platform (2013), Semi-mechanistic Modelling of the Analgesic Effect of Gabapentin in the Formalin-Induced Rat Model of Experimental Pain, Pharm Res 31(3): 593-606.
  • Wang C., Allegaert K., Peeters M.Y., Tibboel D., Danhof M. & Knibbe C.A. (2013), The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults, Br J Clin Pharmacol 77(1): 149-59.
  • Pilla Reddy V., Kozielska M., Johnson M., Mafirakureva N., Vermeulen A., Liu J., Greef R. de, Rujescu D., Groothuis G.M., Danhof M. & Proost J.H. (2013), Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale , Journal of Clinical Psychopharmacology 33(6): 731-9.
  • Knibbe C.A., Tibboel D., Wildt S.N. de, Hoog M. de, Tjoeng M.M. & Danhof M. (2013), [Individualized dosing guidelines for children], Nederlands Tijdschrift voor Geneeskunde 157(16): A4214.
  • Chain A.S., Sturkenboom M.C., Danhof M. & Della Pasqua O.E. (2013), Establishing in vitro to clinical correlations in the evaluation of cardiovascular safety pharmacology., Drug Discovery Today 10(3): 373-83.
  • Wang C., Sadhavisvam S., Krekels E.H., Dahan A., Tibboel D., Danhof M., Vinks A.A. & Knibbe C.A. (2013), Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent model , Clinical Drug Investigation 33(7): 523-34.
  • Stringer F., Ploeger B.A., DeJongh J., Scott G., Urquhart R., Karim A. & Danhof M. (2013), Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar , International Journal of Clinical Pharmacology and Therapeutics 53(3): 256-63.
  • De Cock R.F., Allegaert K., Sherwin C.M., Nielsen E.I., Hoog M. de, Anker J.N. van den, Danhof M. & Knibbe C.A. (2013), A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates, Pharm Res 31(3): 754-67.
  • Taneja A., Nyberg J., Lange E.C. de, Danhof M. & Della Pasqua O. (2012), Application of ED-optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain, JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 39(6): 673-681.
  • Press R.R., Ploeger B.A., Hartigh J. den, Straaten R.J.H.M. van der, Pelt J. van, Danhof M., De Fijter J.W. & Guchelaar H.J. (2007), Improved dose prediction of tacrolimus in de novo kidney transplant patients with population pharmacokinetic modelling including genetic polymorphisms., Bootcongres 2007. Wetenschappelijke voorjaarsvergadering van de Ned. Transplantatie Vereniging : 63.
  • Press R.R., Ploeger B.A., Hartigh J. den, Bemelman F.J., Homan van der Heide J.J., Danhof M., Guchelaar H.J. & Fijter J.W. de (2007), TDM of Everolimus in Stable Renal Transplant Patients after CNI Withdrawal., Therapeutic Drug Monitoring 29(4): 488-488.
  • Press R.R., Ploeger B.A., Hartigh J. den, Straaten R.J.H.M. van der, Pelt J. van, Danhof M., Fijter J.W. de & Guchelaar H.J. (2007), Dose Prediction of Tacrolimus in de novo Kidney Transplant Patients with Population Pharmacokinetic Modelling Including Genetic Polymorphisms., Therapeutic Drug Monitoring 29(4): 530-530.
  • Press R.R., Ploeger B.A., Hartigh J. den, Straaten R.J.H.M. van der, Pelt J. van, Danhof M., Fijter J.W. de & Guchelaar H.J. (2007), Improved Dose Prediction of Tacrolimus in De Novo Kidney Transplant Patients with Population Pharmacokineetic Modelling Including Genetic Polymorphisms., American Journal of Transplantation 7(suppl.2): 440-440.
  • Press R.R., Hartigh J. den, Cremers S.C.L.M., Danhof M., Fijter J.W. de & Guchelaar H.-J. (2006), Dose dependent drug disposition of tacrolimus, Bootcongres 2006 : 51-51.
  • Press R.R., Ploeger B., Hartigh J. den, Cremers S.C.L.M., Danhof M., Fijter J.W. de & Guchelaar H.-J. (2006), Population pharmacokinetics of ciclosporine in kidney transplant patients, Bootcongres 2006 : 27-27.
  • Danhof M. (1998), Whole animal receptor oriented PK/PD for early acceleration of drug development (Lezing). Wiesbaden, Germany.
  • Danhof M. (1998), Whole animal receptor oriented PK/PD for early acceleration of drug development (Lezing). Ann Arbor, USA.
  • Danhof M. (1998), Whole animal receptor oriented PK/PD for early acceleration of drug development (Lezing). McClean, Virginia, USA.
  • Danhof M. (1998), Measurement and kinetics of in vivo drug effects, Summary, conclusions and perspectives (Lezing). Noordwijkerhout, NL.
  • Danhof M. (1998), Whole animal receptor oriented PK/PD as a predicitive tool for clinical trials (Lezing). Stockholm, Sweden.
  • Danhof M. (1998), Whole animal receptor oriented PK/PD for early acceleration of drug development (Lezing). Zagreb, Croatia.
  • Danhof M. (1998), Whole animal receptor oriented PK/PD for early acceleration of drug development (Lezing). Turnhout, Belgium.

Links

Link naar deze pagina
http://hoogleraren.leidenuniv.nl/id/3453

©2015 Universitaire Bibliotheken Leiden www.bibliotheek.leidenuniv.nl